医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Traditional Chinese Medicine Included in the International Classification of Diseases

2020年12月09日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

In 2019, the World Health Assembly approved the 11th Revision of the International Classification of Diseases, which for the first time included the traditional Chinese medicine inside. That is a valuable achievement made by the Chinese government and traditional Chinese medicine experts after continuous efforts of more than 10 years.

Formulated and promulgated by the WHO, The International Classification of Diseases has provided the world with internationally unified disease classification standards. Including traditional Chinese medicine inside can facilitate people to collect statistics of who and how they use TCM, evaluate its effectiveness and safety, and compare TCM-related data with western medical data, which means that traditional Chinese medicine is being gradually integrated with western medicine and accepted by the world.

The inclusion of traditional Chinese medicine into the International Classification of Diseases is inseparable with the quiet but positive efforts of Chinese pharmaceutical enterprises, which have devoted themselves to the development of TCM for a long time. Yiling Pharmaceutical is one of them, it has worked hard to absorb the essence of ancient TCM theories and modern TCM research achievements and developed the famous Lianhua Qingwen Capsules which has good effects of broad-spectrum antiviral, bacteriostatic, antipyretic and antiphlogistic, relieving cough and sputum, and improving cellular immune function, etc. With its excellent efficacy, Lianhua Qingwen has been playing an important role in China’s public health events. Yiling Pharmaceutical is not only a beneficiary but also a promoter for the inclusion of traditional Chinese medicine into the International Classification of Diseases.

With the growing influence of traditional Chinese medicine in the world, Yiling Pharmaceutical has also begun to stand out. Up to now, Lianhua Qingwen Capsules has obtained approval certificates from nearly 20 countries, including Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos, and has officially entered the Philippine market on November 23.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005486/en/

CONTACT

First Name: Li

Last Name: Kristy

E-mail: kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单